Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

0(0%)

Results Posted

50%(1 trials)

Phase Distribution

Ph not_applicable

25%

Ph phase_3

25%

Ph phase_1

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

2(50.0%)

Phase 3Large-scale testing

1(25.0%)

N/ANon-phased studies

1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Other(2)

Detailed Status

unknown2

Completed2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 12 (50.0%)

Phase 31 (25.0%)

N/A1 (25.0%)

Trials by Status

unknown250%

completed250%

Recent Activity

0 active trials

Showing 4 of 4

unknownnot_applicable

Bazedoxifene as a Concomitant Treatment of Patients With Metastatic Pancreatic Adenocarcinoma

NCT04812808

completedphase_1

HDDO-1614 Intervention Trial

NCT03234244

unknownphase_1

AK-R215 Pharmacokinetic Study Phase I

NCT03321318

completedphase_3

Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

NCT00808132

Clinical Trials (4)

Showing 4 of 4 trials

NCT04812808Not Applicable

Bazedoxifene as a Concomitant Treatment of Patients With Metastatic Pancreatic Adenocarcinoma

Unknown

NCT03234244Phase 1

HDDO-1614 Intervention Trial

Completed

NCT03321318Phase 1

AK-R215 Pharmacokinetic Study Phase I

Unknown

NCT00808132Phase 3

Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4